Symptomtext
administered Fluzone High Dose to a patient who is 56 years old, with no reported adverse event; administered Fluzone High Dose to a patient who is 56 years old, with no reported adverse event; Initial information regarding an unsolicited valid non serious case was received from other health professional and consumer or non-health professional via Medical Information (Reference number: 00812383) and transmitted to Sanofi on 14-Oct-2021. This case involved a 56-year-old patient who received INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT] (product administered to patient of inappropriate age and overdose). Patient medical history, past medical treatment, vaccination, family history and concomitant medication were not provided. On 13-Oct-2021, the patient received a 0.7 mL dose of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [Solution for injection in pre-filled syringe, frequency: once, dose: 0.25 mL to 2 mL for vaccines or 0.1 mL for tuberculin (TB) skin test 0.7ML, Strength: standard except for fluzone HD, lot UJ769AC, expiry date: 30-Jun-2022] via an intramuscular route in the right deltoid for prophylactic vaccination. This was actual medication error case due to Inappropriate age at vaccine administration and vaccine overdose. It was reporter "caller reported last night a family of 4 who are all under the age of 65 were giving the FLUZONE HIGH-DOSE VACCINE. Caller reported there are no AE's at this time, but wanted to make sure there was nothing to expect and what they should do from here." no other vaccines. At the time of this report the patient was fine and had no adverse events after the vaccination. This suspected adverse reaction report was submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error was in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party had contributed to or is to be held liable for the occurrence of this medication error.